Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Universita Commerciale Luigi Bocconi |
| Country | Italy |
| Start Date | Jan 01, 2023 |
| End Date | Dec 31, 2025 |
| Duration | 1,095 days |
| Number of Grantees | 18 |
| Roles | Associated Partner; Participant; Coordinator; Third Party |
| Data Source | European Commission |
| Grant ID | 101095593 |
The variety of innovative technologies with the potential to revolutionize the delivery of health care means that the policy toolbox will need several pricing and payment models, adapted in their design and implementation according to the specific situation.
Although there are examples of novel pricing and payment models, the lack of appropriate data infrastructure, legal barriers and unwillingness to adapt current systems often prevent their use.
Therefore, the overall objectives of the Health Innovation Next Generation Pricing Models (HI PRIX) project are: i) to map and formulate new pricing and payment schemes that can be used across technology classes, therapeutic areas, setting and healthcare systems/geographies together with a related set of principles that may guide successful adjustment and flexible implementation to the context of use; ii) to investigate the impact on competitiveness, innovation, equity and affordability of a pipeline of contracting modalities for health innovations; iii) to address the challenges and concerns of payers, manufacturers, healthcare professionals, and patients about different models of pricing by sustaining an effective dialogue across stakeholders groups about the trade-offs between affordability, innovation and patient access.
Coordinated by Bocconi University, the HI-PRIX Consortium involves 18 partners from 10 European countries, including academic institutions, public authorities, healthcare providers, and independent research organizations.
Through theoretical models, quantitative simulation, qualitative research work and case-studies, this three-year project structured around 10 WPs, will generate new evidence on the role of public sector in R&D and indirect medical and environmental costs in pricing and reimbursement determinations, on the pricing dynamics over pharmaceutical products lifecycle, on the impact of policies and incentives on the competitiveness, innovativeness and equity in the healthcare system.
The Office of Health Economics; Servei Catala de la Salut; Imperial College of Science Technology and Medicine; London School of Hygiene & Tropical Medicine; Escuela Andaluza de Salud Publica Sa; Hta Austria - Austrian Institute for Health Technology Assessment Gmbh; Universita Commerciale Luigi Bocconi; University of Hamburg; Universite Libre de Bruxelles; Universidade Nova de Lisboa; Vilniaus Universitetas; Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer; Agenzia Italiana Del Farmaco; Hospital Clinic de Barcelona; Erasmus Universiteit Rotterdam; Infarmed - Autoridade Nacional Do Medicamento E Produtos Da Saude Ip; Fundacion Publica Andaluza Progreso Y Salud M.P.; Ecole D'Economie de Paris
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant